Drug Profile
Respiratory syncytial virus vaccine - CompuVax
Latest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator CompuVax
- Class Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 14 Sep 2023 Discontinued - Preclinical for Respiratory syncytial virus infections in USA (unspecified route) (CompuVax pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA
- 09 Nov 2016 The University of Washington receives patent allowance for Respiratory syncytial virus vaccine antigens in Japan